• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
A mathematical model for maximizing the value of phase 3
A mathematical model for maximizing the value of phase 3

enclosure-v
enclosure-v

... Richly et al., have developed sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid tumours. Eighteen patients with inoperable HCC received doxorubicin 60 mg/m2 IV ...
Effect of Fruit/Vegetable-Drug Interactions on CYP450, OATP and p
Effect of Fruit/Vegetable-Drug Interactions on CYP450, OATP and p

... CYP2A2, CYP3A1, CYP1B1, CYP2B1, CYP2B2, CYP2C1, CYP2C6, CYP2E1 can be inhibited by some vegetables. Antihypertensives, antidiabetics, statins, analgesics and antipsychotics were the most common drugs interacting with fruits and vegetables. The inhibition of their metabolism by fruits and vegetables ...
Brother Can You Spare a Drug - Scholarly Commons at Hofstra Law
Brother Can You Spare a Drug - Scholarly Commons at Hofstra Law

... are infected with the HIV virus and whose immune system cells have been depleted, but who show few or no AIDS symptoms. See Hilts, AIDS Drug's Maker Cuts Price By 20%, N.Y. Times, Sept. 19, 1989, at Al, col. 1. Furthermore, studies have shown that AZT is often intolerable by patients with AIDS due t ...
Pharmacokinetics of Drug Absorption
Pharmacokinetics of Drug Absorption

... Significance of Absorption Rate Constants The overall rate of systemic drug absorption from an orally administered solid dosage form encompasses many individual rate processes, including dissolution of the drug, GI motility, blood flow, and transport of the drug across the capillary membranes and in ...
Glucosamine + Chondroitin with Manganese
Glucosamine + Chondroitin with Manganese

Comparative pharmacology of the H antihistamines
Comparative pharmacology of the H antihistamines

Misoprostol
Misoprostol

... – improve safety profile ...
Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate
Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate

... For example, the reaction conditions for [18 F]FES synthesis in the GE TRACERlab MXFDG system [9] may not be identical to those needed when other automated synthesizers are used for the same synthesis. The first synthesis of [18 F]FES was reported by Kiesewetter et al. [12]. In past few years, sever ...
Drug Interaction and Food - KSU Faculty Member websites
Drug Interaction and Food - KSU Faculty Member websites

... drugs In both the United States and Canada, herbs are currently classified as dietary supplements. The law, declared by the Dietary Supplements Health and Education Act (DSHEA) in 1994, defines a dietary supplement as a vitamin, mineral, amino acid, herb or other botanical combination (Noonana and N ...
Protocol S1.
Protocol S1.

The Absorption, Distribution, and Excretion of Drugs
The Absorption, Distribution, and Excretion of Drugs

... group of healthy adults a standard dose of drug X intravenously (IV) or orally at the start of the study. Blood is drawn from the study subjects repeatedly, at predetermined times, and analyzed for the amount of drug per volume of blood at each point in time. The value obtained is the serum or plasm ...
product monograph trusopt
product monograph trusopt

... The following drug interaction has been associated with the dorzolamide component of TRUSOPT® or with other sulfonamides: Acid-base Disturbances TRUSOPT® is a carbonic anhydrase inhibitor and although administered topically, is absorbed systemically. In clinical studies, TRUSOPT® was not associated ...
Niosome and Proniosome – Vesicular Structured Dosage Form for
Niosome and Proniosome – Vesicular Structured Dosage Form for

... Drug targeting is a specific form of drug delivery where the pharmacological agent is directed selectively to its site of action or absorption. The specific site may be a particular organ, structure, cell or an intracellular region. Targeted drug delivery is a method of delivering medication to a pa ...
The rise and fall of the COX-2 inhibitors
The rise and fall of the COX-2 inhibitors

... exchange adverse drug reactions. This is essential to ensure that rapid and appropriate responses are made to potential safety issues related to medicinal products. The various regulatory restriction of the COX-2 inhibitors go to show the extreme importance of post-market surveillance which include ...
PowerPoint 簡報 - kitasato
PowerPoint 簡報 - kitasato

... • If 1st item fails but not for the rest of it, can we conclude that there is an ethnic difference??? • PK/PD profile may not be able to judge the ethnic difference if few evaluated items do not fit well • According ICH E5, the acceptability of foreign data should be evaluated based on similarity of ...


... which was approximately twice that of a MDI, with less variability. The authors suggested that a less wellcontrolled inhalation procedure than that used in their study could have resulted in a greater difference between the two devices. This suggestion is confirmed by clinical studies showing that b ...
Dose Escalation in Preclinical Toxicology and Pharmacodynamic
Dose Escalation in Preclinical Toxicology and Pharmacodynamic

patrick_tb_ch09
patrick_tb_ch09

Daclatasvir - Daklinza - Bristol
Daclatasvir - Daklinza - Bristol

... signs, body-weight losses, and reduced food consumption) was noted at doses of 200 and 1000 mg/kg/day. In the offspring, malformations of the fetal brain, skull, eyes, ears, nose, lip, palate, or limbs were observed at doses of 200 and 1000 mg/kg. The dose of 1000 mg/kg was associated with profound ...
Nature`s
Nature`s

...  Safety: good but a few case reports of liver toxicity. Safety in women with existing breast cancer is uncertain.  Drug interactions: weak 2D6 induction?  Product selection: standardized root extract; 20mg BID; Remifemin is the best tested.  Questions remaining include  What is the risk in brea ...
the Medicinal Products Act §24
the Medicinal Products Act §24

... requirement would prevent the execution of a scientifically motivated trial with proper patient safety. It is underlined that an attempt must have been made to obtain a notification. ...
Choose the Only FDA-approved Hyaluronidase
Choose the Only FDA-approved Hyaluronidase

Kinetics of Oral Dosing
Kinetics of Oral Dosing

Drugs with antimuscarinic effects
Drugs with antimuscarinic effects

< 1 ... 43 44 45 46 47 48 49 50 51 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report